The estrogen receptor-a gene (ESR1) was previously identified as a direct target of the homeobox transcription factor BARX2 in MCF7 cells. Here, we show that BARX2 and ESR1 proteins bind to different ESR1 gene promoters and regulate the expression of alternatively spliced mRNAs that encode 66 and 46 kDa ESR1 protein isoforms. BARX2 increases the expression of both ESR1 isoforms; however, it has a greater effect on the 46 kDa isoform, leading to an increased ratio between the 46 and 66 kDa proteins. BARX2 also influences estrogen-dependent processes such as anchorage-independent growth and modulates the expression of the estrogen-responsive genes SOX5, RBM15, Dynein and Mortalin. In addition, BARX2 expression promotes cellular invasion and increases the expression of active matrix metalloproteinase-9 (MMP9). BARX2 also increases the expression of the tissue inhibitor of metalloproteinase (TIMP) genes, TIMP1 and TIMP3, in cooperation with estrogen signaling. Overall, these data indicate that BARX2 and ESR1 may coordinately regulate cell growth, survival and invasion pathways that are critical to breast cancer progression.
Introduction
Homeodomain transcription factors drive development by regulating regional patterns of gene expression that control diverse cellular behaviors such as differentiation, proliferation, adhesion, migration and apoptosis (Fienberg et al., 1987; Mark et al., 1997) . Homeobox genes can also contribute to breast cancer progression by influencing cell cycle regulation, apoptosis, angiogenesis and metastasis (Care et al., 2001; Samady et al., 2004; Satoh et al., 2004) .
We previously characterized a homeodomain protein Barx2 that is expressed in several tissues during mouse development, including cartilage, muscle and branching epithelial structures such as the mammary and lacrimal glands (Jones et al., 1997; Herring et al., 2001; Meech et al., 2003; and unpublished observations) . Barx2 controls processes involving cell adhesion and cytoskeletal remodeling, including myogenesis and chondrogenesis (Meech et al., 2003 (Meech et al., , 2005 . Human BARX2 has been described as a potential tumor suppressor gene in ovarian cancer, where its loss correlates with invasiveness, and ectopic expression inhibits invasion (Sellar et al., 2001) . Recently, we found that BARX2 is expressed in estrogen-dependent (MCF7 and T47D) but not estrogen-independent (MDA-MB-231) breast cancer cell lines (Stevens et al., 2004) . Moreover, chromatin immunoprecipitation (ChIP) and RNAmediated inhibition (RNAi) of BARX2 identified the estrogen receptor-a gene (ESR1) as a direct target of BARX2 in MCF7 cells (Stevens et al., 2004) .
Estrogen is a critical regulator of mammary gland proliferation and differentiation. Upon binding estrogen, ESR1 translocates to the nucleus where it binds to DNA sequences called estrogen response elements (EREs) and interacts with various co-activators and co-repressors. ESR1 also interacts with other transcription factors that bind to DNA in a combinatorial manner (Smith et al., 1996; Heery et al., 1997; Hong et al., 1997; McDonnell, 1999) .
The ESR1 gene is transcribed from six different promoters (Figure 1) , producing mRNAs containing different 5 0 UTRs (Flouriot et al., 1998) . These may be translated into full-length 66 kDa ESR1 (ESR1-66), or alternatively spliced to produce truncated forms of the protein. In particular, an mRNA lacking exon 1 is translated from an initiation codon in exon 2, generating a truncated 46 kDa protein (ESR1-46) that lacks the N-terminal ligand-dependent activation function. ESR1-46 does not activate gene expression in response to estrogen and can function in a dominant-negative manner by binding to ESR1-66 and blocking its liganddependent activation function (Flouriot et al., 2000; Metivier et al., 2004) . ESR1-46 is expressed in breast cancer cell lines, mammary gland and osteoblasts (Fasco et al., 2000; Flouriot et al., 2000) . In osteoblasts, competition between ESR1-46 and ESR1-66 for DNA binding leads to reduced cell proliferation (Denger et al., 2001) , and in other cell types, expression of ESR1-46 can inhibit the growth stimulatory effect of ESR1-66 (Penot et al., 2005) .
During normal breast development, proliferation of mammary epithelial cells is coordinated with invasion into the surrounding extracellular matrix (ECM). This process is known as branching morphogenesis and is mediated by ECM-degrading enzymes such as matrix metalloproteinases (MMPs). Invasion is tightly regulated and self-limiting, and the spatial and temporal expression and activation of MMPs are rigidly controlled by multiple mechanisms. Matrix metalloproteinases are synthesized as inactive zymogens (pro-MMPs) and are processed to active forms by proteolytic cleavage (Sternlicht and Werb, 2001) . Tissue inhibitors of metalloproteinases (TIMPs) bind and reversibly inhibit MMPs (Gomez et al., 1997) ; coordination of these two families is critical for proper mammary gland development. A hallmark of breast cancer progression is invasion of the ECM (Stetler-Stevenson, 1990) , which frequently involves misregulation of MMPs or TIMPs; increased expression and activation of MMPs has been correlated with increased invasion and metastases of many human cancers (Egeblad and Werb, 2002 ).
In the current study, we find that BARX2 expression can promote both anchorage-independent growth (AIG) and cellular invasion of MCF7 cells. BARX2 and ESR1 bind to the ESR1 gene and regulate the expression of alternatively spliced mRNAs that encode the ESR1-46 and ESR1-66 isoforms. BARX2 also interacts functionally with estrogen in the regulation of several target genes that may be involved in both growth and invasion pathways, including MMP and TIMP genes. Together, these data suggest that BARX2 and ESR1 coordinate cellular growth, survival and invasion, and may regulate both breast cancer progression and normal mammary gland development.
Results

BARX2 and E 2 treatment alter the expression of different ESR1 isoforms
To determine if BARX2 regulates ESR1 expression, cells that stably overexpress BARX2 (MCF7-pcBARX2) and control cells (MCF7-pcDNA3) were immunoblotted with ESR1 antibodies. As ESR1 expression is also modulated by estrogen signaling, the cells were cultured in steroid-depleted media containing charcoal-stripped serum (CSS media) with or without 17-b-estradiol (E 2 ; Sigma, St Louis, MO, USA). Several ESR1 protein isoforms were identified, including ESR1-66 and ESR1-46 ( Figure 2a ). Overexpression of BARX2 caused a twofold increase in the expression of ESR1-66 and nearly fivefold increase in ESR1-46 over control cells (Figure 2b) . Thus, the ESR1-46/ESR1-66 ratio was approximately 0.17 in MCF7-pcDNA3 cells and 0.56 MCF7-pcBARX2 cells. However, with E 2 stimulation, the ESR1-46/ESR1-66 ratio was essentially the same in both cell lines. Thus, BARX2 upregulates the expression of both ESR1 isoforms; however, it has a greater effect on ESR1-46 expression, resulting in an increased ESR1-46/ESR1-66 ratio. Moreover, E 2 antagonizes the effect of BARX2.
Given that BARX2 can bind to the ESR1 gene, it seemed likely that the differential regulation of ESR1-46 and ESR1-66 isoform expression by BARX2 and E 2 occurs at the level of transcription and splicing. ESR1-66 may be encoded by mRNAs that are transcribed from all six ESR1 gene promoters, whereas ESR1-46 is encoded only by mRNAs transcribed from promoters located upstream of exon E1 or F (Figure 1) (Flouriot et al., 2000) . Exons E1 or F are spliced to exon E2, which is subsequently spliced to exon 2, creating an mRNA that lacks exon 1 (Dexon1). The previously identified BARX2 binding site is located upstream of exon E2 (Figure 1 ), prompting the idea that binding of BARX2 might directly affect the transcription and/or splicing of the ESR1-46 isoform. Quantitative reverse transcriptase-polymerase chain reaction (Q-PCR) was used to measure Dexon1 mRNA production in control and BARX2-overexpressing cells cultured in CSS media. MCF7-pcBARX2 cells expressed twofold greater Dexon1 mRNA than did control cells (Figure 2c) , and E 2 antagonized this effect. Thus, increased Dexon1 mRNA production may contribute to the increased ESR1-46/ESR1-66 ratio observed in MCF7-pcBARX2 cells in the absence of E 2 .
BARX2 and ESR1 bind to alternative ESR1 gene promoters The E1 and F promoter regions contain several potential homeobox binding sites with the core recognition sequence TAAT. In addition, promoter F contains 0 region of the human ESR1 gene. Non-coding exons E1-A are distributed over 150 kb upstream of exon 1. Each exon has a unique promoter, except for exon E2. Transcripts initiating upstream of exons E1 or F are spliced to exon E2, which may be subsequently spliced to exon 1 producing the full-length mRNA encoding ESR1-66, or to exon 2 producing the Dexon1 mRNA encoding ESR1-46. The star indicates a BARX2 binding fragment previously identified by chromatin immunoprecipitation (ChIP).
an ERE half-site that might bind ESR1. To determine whether BARX2 and ESR1 bind to these promoters, ChIP assays were performed using antibodies specific to each protein. Immunoprecipitated DNA was amplified using PCR primers that spanned regions immediately upstream of exons E1 and F. Chromatin immunoprecipitation using BARX2 antibodies strongly enriched DNA corresponding to promoters E1 and F, whereas ESR1 ChIP preferentially enriched promoter F DNA (Figure 2e ). This indicates that BARX2 can bind directly to upstream promoters E1 and F, whereas ESR1 is recruited to promoter F primarily. As promoter use is known to affect alternative splicing events (Cramer et al., 1997 (Cramer et al., , 1999 , the differential binding of BARX2 and ESR1 to the E1 and F promoters of ESR1 might function to regulate the splicing events that determine which ESR1 isoform is produced.
BARX2 induces anchorage-independent growth of MCF7 cells
The observation that BARX2 controls the expression of ESR1 prompted us to examine whether it might affect cellular responses to E 2 . Transformed cells can grow in anchorage-independent conditions as measured by colony formation in soft agar; however, AIG of MCF7 cells requires either estrogen or growth factor stimulation (Zugmaier et al., 1991) . When MCF7-pcBARX2 and control MCF7-pcDNA3 were embedded in soft agar with growth media (GM), MCF7-pcBARX2 cells formed colonies whereas control cells did not ( Figure 3a) . Supplementary E 2 (10 nM) was necessary for colony formation to occur in control cells. In contrast, in CSS media neither control nor MCF7-pcBARX2 cells survived in soft agar, although addition of E 2 induced AIG in both cell types (not shown). Thus, BARX2 expression can induce AIG in MCF7 cells when low levels of estrogenic factors are present; however, it does not render the cells completely independent of E 2 . Interestingly, control and BARX2-overexpressing cells proliferated at the same rate when cultured as monolayers on plastic (not shown), suggesting that the stimulatory effect of BARX2 is restricted to anchorage-independent (tumorigenic) growth.
To determine whether increased ESR1 expression drives AIG in MCF7-pcBARX2 cells, stable cell lines overexpressing the ESR1-66 or ESR1-46 proteins were generated ( Figure 3b ). Overexpression of ESR1-66 induced AIG in soft agar, whereas overexpression of ESR1-46 did not. Thus, the BARX2-induced increase in ESR1-66 expression might promote AIG, whereas ESR1-46 is unlikely to contribute to this phenomenon.
BARX2 and estrogen coordinately regulate gene expression A number of previously identified BARX2 target genes (Stevens et al., 2004) are also E 2 responsive as shown by Serial Analysis of Gene Expression (see http://science park.mdanderson.org/ggeg). Quantitative RT-PCR was used to examine whether BARX2 and E 2 might coordinately regulate the expression of a selected number of these genes (Figure 4 ). BARX2 and E 2 independently increased the expression of the RBM15 and dynein light chain (DNLC1) genes. However, E 2 treatment of BARX2-overexpressing cells resulted in a significant decrease in the expression of both of these genes (Figure 4a and b) , indicating that E 2 antagonizes the effect of BARX2 on RBM15 and DNLC1. Antagonism was also observed with Mortalin gene expression, although for this gene the effect was the inverse, that is, Mortalin expression was repressed in MCF7-pcBARX2 cells to 10% of that in control cells, whereas E 2 treatment restored Mortalin expression to nearly 50% of control levels ( Figure 4c ). E 2 did not affect Mortalin expression in controls, suggesting that it specifically antagonizes BARX2-mediated repression of this gene.
In contrast, two other genes were independently regulated by BARX2 and E 2 . SOX5 gene expression increased nearly threefold and RER1 expression decreased approximately twofold in response to either BARX2 overexpression or E 2 stimulation. However, the effect of combining both treatments was additive, suggesting that these signals function independently (Figure 4d and e). Taken together, these data suggest that target-specific, functional interactions can occur between BARX2 and estrogen signaling.
BARX2 induces invasion of MCF7 cells
To determine whether BARX2 expression altered cell invasiveness, we used a modified Boyden chamber assay. BARX2 overexpression induced invasion of MCF7 cells through 2 mg/ml Matrigel toward the chemoattractant fibronectin within 24 h of seeding, with or without E 2 ( Figure 5a ). As Matrigel and serum contain many factors that might contribute to the ability of BARX2 to induce cell invasion, the assay was repeated, substituting 2 mg/ml collagen IV for Matrigel and using GM, serumfree (SF) or CSS media. In GM, which contains serum, MCF7-pcBARX2 cells migrated through the collagen while the control cells did not, a result similar to that observed for Matrigel. In SF media, neither population invaded the collagen gel, indicating that, in addition to BARX2, a component of serum was required to induce cell invasion. Charcoal-stripped serum media, with or without E 2 , restored the ability of MCF7-pcBARX2 cells to invade the collagen IV gel (Figure 5a , bottom panels), indicating that BARX2-induced invasion is independent of E 2 but requires factors present in the serum.
The ability of cells to migrate through Matrigel is influenced by Matrigel concentration, the type of chemoattractant used and cell density. When MCF7 cells were embedded in 5 mg/ml Matrigel (diluted 1:1 with GM) at fivefold higher density than in the invasion assay and without a chemoattractant, MCF7-pcBARX2 cells migrated toward each other to form aggregates, whereas MCF7-pcDNA3 cells did not (Figure 5b ). The aggregation effect is consistent with the observed role of BARX2 in increasing adhesion of other cells (Meech et al., 2005) . We also plated MCF7 cells at low density in 10 mg/ml (undiluted) Matrigel with fibroblast growth factor (FGF)-2 as described for branching morphogenesis assays (Liu et al., 2001) . In this context, MCF7-pcBARX2 cells did not migrate but proliferated into colonies that resemble the spheroids formed by untransformed mammary epithelial cells (Debnath et al., 2003) . They also developed bud-like membrane protrusions. In contrast, MCF7-pcDNA3 cells proliferated poorly, forming very small colonies with no buds (Figure 5c ).
BARX2 influences the expression of active matrix metalloproteinase-9
To examine the possibility that BARX2 induces invasion by increasing ECM degradation, we used gelatin zymography to measure MMP2 and MMP9 activity of cells on plates and in Matrigel. BARX2 did not alter MMP9 levels when the cells were grown on plates (not shown); however, in Matrigel MCF7-pcBARX2, cells showed 2.5-fold higher levels of pro-and active MMP9 than control cells (Figure 6a and b) . E 2 did not alter this response. MMP2 levels were not increased in either condition, indicating that BARX2 regulates MMP9 expression specifically.
To determine whether the upregulation of MMP9 by BARX2 was transcriptional, mRNA levels were examined using RT-PCR. On plates, MMP9 mRNA was increased twofold by BARX2 and fourfold by the combination of BARX2 and E 2 . In Matrigel, BARX2 increased MMP9 expression approximately sevenfold, independent of E 2 stimulation (Figure 6c) . Thus, in different contexts BARX2 can synergize with either estrogen or signals induced by three-dimensional culture in synthetic ECM to regulate MMP9.
BARX2 and E 2 regulate the expression of tissue inhibitor of metalloproteinases
The earlier observation that BARX2 binds to the TIMP4 gene in MCF7 cells (Stevens et al, 2004) prompted us to examine the effect of BARX2 on TIMP mRNA levels using RT-PCR. On plates and in Matrigel, MCF7-pcBARX2 cells had 1.5-2-fold higher TIMP4 expression than control cells (Figure 7c ). E 2 also increased TIMP4 expression approximately twofold in both conditions, but did not synergize with BARX2.
BARX2 and E 2 had a greater effect on other TIMP genes. In Matrigel, TIMP1 was increased twofold by BARX2 and fivefold by the combination of BARX2 and E 2 (Figure 7a) . Similarly, TIMP3 was increased sevenfold by BARX2 and 13-fold by BARX2 and E 2 (Figure 7b ). E 2 alone had no effect indicating synergism with BARX2. Moreover, BARX2 and E 2 had a much more modest effect on these genes when cells were grown on plates. Thus, as with MMP9, the ability of BARX2 to regulate TIMPs is influenced by both estrogen and ECM. (dark gray bars), pro-MMP9 (medium gray bars) and active MMP9 (light gray bars) levels were measured. The level of MMP9 in MCF7-pcDNA3 cells without E 2 was used as a reference standard and set to 1 (stippled line). (c) MCF7-pcDNA3 and MCF7-pcBARX2 cells were cultured on plates (dark gray bars) or in Matrigel (light gray bars) in CSS media, E 2 was added as indicated. MMP9 gene expression was determined by Reverse transcriptase-polymerase chain reaction (RT-PCR). MMP9 expression in MCF7-pcDNA3 cells without E 2 was used as a reference standard and was set to 1 (stippled line). Experiments were performed in triplicate.
Discussion
Decreased estrogen dependence in breast tumors usually correlates with a more invasive phenotype, and poor prognosis. BARX2 is expressed in estrogen receptorpositive breast cancer cell lines and data presented here indicate that it influences both estrogen-dependent growth and cellular invasion.
Anchorage-independent growth is a hallmark of cellular transformation (Shin et al., 1975) . BARX2 induced AIG of MCF7 cells in response to very low estrogen levels, suggesting that it enhanced sensitivity to estrogen. This may reflect increased ESR1-66 expression, which could also promote AIG. In contrast, increased ESR1-46 expression did not induce AIG. Moreover, ESR1-46 can compete with ESR1-66 in a variety of contexts and inhibit monolayer growth in response to estrogen (Penot et al., 2005) . Thus, the increased ESR1-46/ESR1-66 ratio in BARX2-overexpressing cells may seem at odds with increased AIG. However, it is possible that the regulatory network underlying AIG is not sensitive to inhibition by ESR1-46, or that other BARX2 targets antagonize the inhibitory function of ESR1-46. For example, the BARX2 target gene DNLC1 was recently shown to promote both transactivation by ESR1 and AIG (Rayala et al., 2005) .
The cooperative and antagonistic effects of BARX2 and estrogen on different target genes are not easily explained by the altered expression of ESR1 isoforms and might indicate a functional interaction between the BARX2 and ESR1 proteins. This idea is supported by our recent observation that BARX2 can bind to at least two co-activators known to mediate ESR1 transactivation (manuscript in preparation), suggesting that they could be present in the same regulatory complexes.
BARX2 increased transcription of the Dexon1 ESR1 mRNA and this was abrogated by E 2 . BARX2 binds strongly to the E1 and F promoters, whereas ESR1 primarily binds to the F promoter; this differential binding might influence promoter use and thus alternative splicing. ESR1 was shown to regulate splicing of a synthetic minigene driven by an estrogen-responsive promoter in cooperation with the transcriptional coregulators COAA and CAPER (Auboeuf et al., 2002 (Auboeuf et al., , 2004 (Auboeuf et al., , 2005 . It will be interesting to determine whether these same co-regulators can interact with BARX2. Promoter F also contains a consensus SOX5 binding site (Lambertini et al., 2003) and BARX2 and E 2 increased expression of this factor. Thus, SOX5 might also play a role in the regulation of promoter F. Overall, our results suggest that the ESR1 gene is an endogenous target of estrogen-mediated regulation of alternative splicing, and that BARX2 and ESR1 might regulate these splicing events by influencing promoter choice.
Cell migration involves cytoskeletal rearrangement, cell-matrix interaction and ECM remodeling. BARX2 might promote serum-dependent migration by any of these mechanisms. For example, BARX2 influences the cytoskeleton (Meech et al., 2003) and interacts with the serum response factor (SRF) (Herring et al., 2001) , which controls actin-directed cell spreading (Schratt et al., 2002) . BARX2 also increases transcription of MMP9, which is known to promote invasion of cancer cells via matrix degradation (Vu et al., 1998; Balduyck et al., 2000; Zhao et al., 2004) . The observed upregulation of TIMPs, including TIMP1 which binds MMP-9 (Nguyen et al., 1998) , may seem inconsistent with the increased invasiveness of BARX2-overexpressing cells. However, TIMPs have many functions in addition to MMP inhibition. For example, TIMP1 activates MAPK Figure 7 BARX2 and 17-b-estradiol (E 2 ) regulate tissue inhibitor of metalloproteinase (TIMP) gene expression in Matrigel. MCF7-pcDNA3 and MCF7-pcBARX2 cells were cultured on plates (dark gray bars) or in Matrigel (light gray bars) in charcoal stripped serum (CSS) media, E 2 was added as indicated. TIMP1 (a), TIMP3 (b) and TIMP4 (c) gene expression was examined using Reverse transcriptase-polymerase chain reaction. The expression of each gene in MCF7-pcDNA3 cells without E 2 was used as a reference standard and set to 1 (stippled line). Experiments were performed in triplicate.
signaling which can increase MMP9 levels and ECM degradation (Liu et al., 2003) . Moreover, TIMP1 is elevated in many malignant breast tumors (Yoshiji et al., 1996) , stimulates growth and inhibits apoptosis under anchorage-independent conditions (Li et al., 1999) . Thus, the combination of specific MMPs and TIMPs, rather than overall MMP/TIMP ratios, may control invasion.
BARX2 had a greater effect on MMP9 and TIMP gene expression when cells were embedded in Matrigel. This is consistent with previous observations that MMPs and TIMPs are regulated by growth factors and cell-ECM interactions. These stimuli trigger signaling cascades that culminate in the activation of transcription factors such as AP1, fos, jun and ETS that bind directly to MMP gene promoters (Chakraborti et al., 2003) . BARX2 might interact with such factors, as it is known to bind to leucine-zipper proteins (Meech et al., 2003) and SRF (Herring et al., 2001) . Estrogen also influenced BARX2-mediated regulation of TIMP1 and TIMP3, consistent with previous observations that steroid hormones regulate TIMPs (Nothnick et al., 2004) . Functional interaction between BARX2 and E 2 might explain the dichotomous observation that ectopic BARX2 expression inhibits invasion of OAW42 ovarian cancer cells (Sellar et al., 2001) , whereas increased BARX2 expression promotes invasion of MCF7 cells. OAW42 cells do not express ESR1 (O'Doherty et al., 2002; Stevens et al., 2004) , thus one factor controlling the effect of BARX2 on cancer cell invasion may be ESR1 expression status.
The regulation of MMPs and TIMPs by the Hox and Pax families of developmental patterning genes has been little studied, although it is known that Pax6 binds the MMP9 promoter (Sivak et al., 2004) and BARX2 binds to the TIMP4 gene (Stevens et al., 2004) . If BARX2 is an intrinsic regulator of MMP and TIMP genes, it might play a role in developmental patterning of the mammary gland. Consistent with this idea, BARX2 is expressed in normal human mammary gland epithelium (Krasner et al., 2000) and influences lacrimal gland branching morphogenesis (unpublished observations). Moreover, the BARX2 targets MMP9, TIMP1 and TIMP3 variously regulate branching morphogenesis in mammary, kidney and bronchiole tissues (Lelongt et al., 1997; Fata et al., 1999; Gill et al., 2003) . Our data suggest that BARX2 responds to ECM signals and regulates genes involved in ECM remodeling, providing a feedback loop that maybe relevant to both breast cancer invasion and normal mammary gland branching morphogenesis.
Materials and methods
Cell culture MCF7 cells were obtained from the American Type Culture Collections and maintained in growth media (GM) consisting of Dulbecco's modified eagle medium (DMEM) supplemented with 10% fetal bovine serum (Invitrogen, Carlsbad, CA, USA), 2 mM L-glutamine, 100 U/ml penicillin and 100 mg/ml streptomycin. For steroid-depleted culture, phenol red-free DMEM was supplemented with 10% charcoal-dextranstripped serum (CSS) plus L-glutamine and antibiotics. Serum-free media (SF) consisted of phenol red-free DMEM with L-glutamine and antibiotics.
Construction of MCF7 cell lines stably expressing BARX2, ESR1-46 and ESR1-66 MCF7-pcDNA3 cells containing the empty expression vector, and MCF7-pcBARX2 cells containing the BARX2 expression vector were described previously (Stevens et al., 2004) . The cells, representing a mixed pool of transformatants with different integration sites, were maintained in GM with 100 mg/ml gentamycin (Invitrogen). Expression vectors encoding the ESR1-46 and ESR1-66 proteins were obtained from Dr Francis Gannon. The cDNAs were subcloned into the pcDNA3 vector and transfected into MCF7 cells by electroporation. Stable transfectants were selected using 100 mg/ml gentamycin. Immunoblotting for ESR1-46 or ESR1-66 was used to identify individual lines or mixed pools that overexpressed the appropriate isoform.
Quantitative immunoblotting MCF7-pcDNA3 and MCF7-pcBARX2 cells were grown in CSS or SF media and 10 nM E 2 was added as required. Cells were harvested after 48 h and total protein was extracted using radioimmunoprecipitation assay buffer. Proteins were resolved by sodium dodecyl sulfate-polyacrylamide gel electrophoresis (SDS-PAGE; Invitrogen), transferred to membranes and probed with anti-ESR1 antibodies (HC-20; Santa Cruz Biotechnologies, Santa Cruz, CA, USA). Blots were stripped and re-probed with anti-b-actin antibodies for normalization.
RNA extraction, cDNA synthesis and quantitative polymerase chain reaction Total RNA was isolated from MCF7 cells using TRIzol (Invitrogen) and treated with DNase (Ambion, Austin, TX, USA). cDNA was prepared using random primers and Moloney-murine leukemia virus reverse transcriptase enzyme (New England Biolabs, Ipswich, MA, USA). Primer sequences are listed in Table 1 . Quantitative PCR was performed as described previously (Stevens et al., 2004) .
Chromatin immunoprecipitation
Chromatin immunoprecipitation was performed on MCF7-pcBARX2 cells using BARX2 antiserum (Santa Cruz Biotechnology), ESR1 antiserum or preimmune rabbit serum (negative control) as described (Stevens et al., 2004) . To increase the resolution of the ChIP analysis, the bound chromatin was digested with NlaIII in the presence of 0.5% NP-40 and washed to remove unbound DNA fragments. Immunoprecipitated DNA was purified as described previously (Stevens et al., 2004) and amplified by PCR with primers located within NlaIII fragments immediately upstream of the E1 and F promoters. Primer sequences were as follows: E1 forward, ATTTTCCCTCACTGTGAAGTGC; E1 reverse, TTTTATCCTGATGTGTGAGGC; F forward, CCTGTC TAGACTTCAAGCTTTATTACGA; F reverse, GAAATT AGGAAATGCAGTAAC.
Anchorage-independent growth assays Cells (1 Â 10 5 ) were mixed with 0.33% (w/v) agarose in GM with or without E 2 and seeded onto dishes coated with 0.5% (w/v) agarose. MCF7-pcDNA3, MCF7-pcBARX2 and MCF7-pcESR1-46 stable pools as well as individual lines of MCF7-pcESR1-46 and MCF7-ESR1-66 transfectants were used. Plates were incubated at 371C for 18-24 days and examined for the appearance of colonies under phase contrast using an Axiovert 10 inverted microscope (Zeiss, Thornwood, NY, USA).
Gelatin zymography
Cells (4 Â 10 5 ) were either seeded directly onto plates or mixed with 3 mg/ml Matrigel (BD Biosciences, San Jose, CA, USA) in SF media and plated onto fibronectin-coated plates. Serumfree media with or without E 2 was added and incubated for 24-120 h at 371C. The conditioned media was concentrated and separated on 10% SDS-polyacrylamide gels containing 0.1% gelatin (Novex) under non-reducing conditions. Gels were processed for zymography as described by the manufacturer. Cells were extracted from Matrigel using Cell Recovery Solution (BD Biosciences) for RNA preparation.
Matrigel and collagen invasion/migration assays Polycarbonate filter Transwells (8 mM pore size; CorningCostar, Acton, MA, USA) were filled with 3 mg/ml Matrigel or collagen IV and overlaid with 1 Â 10 4 cells in various media. Fibronectin (20 mg/ml) was added to the media below the inserts as an attractant. Cells were incubated for 24-120 h at 371C and then stained with 0.2% cresyl violet. Matrigel was removed with a cotton swab and cells that had migrated to the under surface of the filter were examined. In other experiments, 5 Â 10 4 cells were overlaid on 5 mg/ml Matrigel in Transwells without chemoattractant. After 24-96 h, the cells in Matrigel were stained with 0.2% cresyl violet. MCF7 spheroids were grown in Matrigel as described previously (Liu et al., 2001) . Briefly, 2 Â 10 4 cells were embedded in 0.3 ml of or 10 mg/ml ice-cold Matrigel in chamber slides and covered with GM with or without FGF-2 (10 ng/ml). Cells were examined by phase-contrast microscopy from 2 to 18 days for growth and budding. 
